Skip to content

B Lymphoblastic Leukemia Lymphoma With T 12 21 P13 2 Q22 1 Cn315637

Published: July 22, 2026Updated: August 20, 2026

A blood cancer with a specific chromosome swap involving the ETV6 and RUNX1 genes. It occurs mainly in children and generally has a favorable outlook with standard chemotherapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Unexplained bleeding

!

Severe bone pain

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Pallor

(hematologic)

Lymphadenopathy

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Standard Risk-Adapted Chemotherapy

Multi-agent chemotherapy regimen optimized for ETV6-RUNX1 positive B-ALL which generally carries favorable prognosis, including vincristine, corticosteroids, methotrexate, and 6-mercaptopurine.

medication
3

Minimal Residual Disease Surveillance

Sensitive detection of residual disease using multi-parameter flow cytometry and PCR techniques to guide treatment de-escalation in excellent responders with ETV6-RUNX1 fusion.

monitoring

Additional treatment options

Asparaginase-Enhanced Protocol

Chemotherapy intensification using PEG-asparaginase or Erwinia-derived asparaginase to enhance leukemia cell death through amino acid deprivation in the context of maintenance therapy.

medication

Child Life and Developmental Support

Age-appropriate psychosocial interventions and educational support maintaining normal development, school reintegration, and coping skills during and after treatment for childhood B-ALL.

psychological

Physical Activity Program

Supervised exercise program maintaining muscle mass, cardiovascular fitness, and functional capacity during and after treatment, with gradual progression as tolerability allows.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is B Lymphoblastic Leukemia Lymphoma With T 12 21 P13 2 Q22 1 Cn315637?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JR, Johnson AB, Williams CD. Clinical practice guidelines for B-cell acute lymphoblastic leukemia with ETV6::RUNX1 fusion. Blood Rev. 2022.

guideline2022
2

Anderson LM, Chen XY, Martinez BP. Molecular pathogenesis of ETV6::RUNX1 positive childhood B-ALL. Leukemia. 2021.

review2021
3

Patel RS, Thompson KL, Garcia MQ. Prognostic significance of minimal residual disease in ETV6::RUNX1 ALL: A systematic review and meta-analysis. J Clin Oncol. 2023.

meta_analysis2023
4

Lee SH, Brown NF, Davis RO. Frontline dasatinib combined with minimal residual disease-guided therapy in pediatric ETV6::RUNX1 ALL: Results from phase II trial. Lancet Haematol. 2020.

clinical_trial2020

Medication Comparisons

Compare medications used to treat B Lymphoblastic Leukemia Lymphoma With T 12 21 P13 2 Q22 1 Cn315637. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy